With Anoro, GSK Takes A Two-Step Toward Bolstering Respiratory
FDA approved GSK’s Anoro Ellipta as the first LABA/LAMA combination product in the U.S. for the maintenance treatment of COPD Dec. 18, positioning GSK to launch a second respiratory product months after launching Breo Ellipta.
You may also be interested in...
AstraZeneca's Hudson Optimistic On Return To Growth In 2017
US President Paul Hudson talked in an interview at the J.P. Morgan Healthcare conference about the company’s budding oncology portfolio, upcoming launches and growing optimism as the 2017 return-to-growth goal approaches.
GSK’s Breo Ellipta Marches Forward For Asthma, Efficacy Undistinguished From Advair
Follow-on may continue to face adoption challenges with expanded indication despite dosing convenience.
GSK’s Post-Advair Day Has Dawned, But Breo And Anoro Not Yet Shining
Decline in Advair sales to cointinue for several years as the portfolio transitions to new products, which have faced reimbursement challenges.